摘要
目的对3种治疗小儿支气管肺炎的抗生素方案进行药物经济学的成本-效果分析,为临床提供最佳治疗方案。方法采取回顾性研究,抽取我院2009年1月~2009年6月经临床医生确诊为支气管肺炎的出院病历138份,分为A、B、C 3组,分别使用哌拉西林舒巴坦、阿莫西林舒巴坦和头孢呋辛进行治疗,运用药物经济学进行评价,同时进行敏感度分析。结果 3种方案的治疗效果无显著性差异（P〉0.05）,有效率分别为94.12%、95.56%、95.23%;治疗成本分别为1473.68元、1736.93元、1774.56元;有效率每增加1个百分点其成本分别为15.66元、18.18元、18.63元。结论 A方案为治疗小儿支气管肺炎的最佳方案。
OBJECTIVE Evaluated the cost-effectiveness of three therapeutic schemes for children pneumonia used antibiotics so as to provide references for rational use of drugs in the clinic.METHODS A random drawing to 138 cases of children pneumonia in January to June in 2009,which devided to three groups A,B and C,used Piperacillin Sodium and Sulbactam Sodium,Amoxicillin and Sulbactam,Cefuroxime,respectively.The pharmacoeconomic cost-effectiveness analysis was conducted on the three therapeutic regimens by a retrospective study,at the same time,the sensitive analysis was performed.RESULTS There is no significant differences in three therapeutic schemes（P0.05）,the effective rates of schemes were 94.12%,95.56%and 95.23%,respectively;the total costs for the three schemes were 1473.68 yuan,1736.93 yuan and 1774.56 yuan,respectively.The incremental costs for increase of each percentage of the effective were 15.66 yuan,18.18 yuan and 18.63 yuan,respectively.CONCLUSION Therapeutic regimen A is the most reasonable for children pneumonia.
出处
《海峡药学》
2011年第9期204-206,共3页
Strait Pharmaceutical Journal
关键词
支气管肺炎
药物经济学
成本-效果分析
哌拉西林舒巴坦
阿莫西林舒巴坦
头孢呋辛
Bronchopneumonia
Pharmacoeconomics
Cost-effectiveness analysis
Piperacillin Sodium and Sulbactam Sodium
Amoxicillin and Sulbactam
Cefuroxime
